eGain Launches AssistGPT™, First-of-Its-Kind Solution to Automate Knowledge for Customer Engagement
SUNNYVALE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- eGain Corporation (NASDAQ: EGAN), the leading knowledge management platform provider for customer engagement automation, launched eGain AssistGPT™ at its Solve™ 23 conference, being held on September 25, at the Brewery, London.
An integral part of the eGain Knowledge Hub and powered by Generative AI out of the box, AssistGPT is a comprehensive zero-code solution for Knowledge Automation. For example, knowledge content draft creation, which used to take weeks, can now be completed in just a few minutes. The solution also helps customers in their omnichannel journeys with quick answers and contact center agents and business analysts in the flow of their work. An AI Console allows administrators to define guard rails for the use of generative AI, manage prompts, and orchestrate it with other AI technologies in the enterprise.
AssistGPT comes with a best practice prompt library, which enables organizations to add business-specific prompts. Based on a BYO architecture, the solution allows the business to plug in their own AI engines to answer the prompts. Sample out-of-the-box use-cases include:
- AX (Agent Experience)
- Provides answer needle to customer queries from content haystacks
- Summarizes customer conversations
- Improves responses
- KX (Knowledge Author Experience)
- Generate summary and keywords
- Create and set up prompts
- Write, condense, expand, translate, brand-align, or improve knowledge articles
- BX (Business managers and analysts)
- Extract insights from customer feedback and reports
- Get executive summary of insights and actions
- Create knowledge content suggestions
"Generative AI takes effort out of knowledge management. KM offers reliable content, business controls, and analytics for generative AI," said Ashu Roy, eGain CEO. "Together, they deliver transformational value in customer engagement."
More information
AssistGPT: www.eGain.com/solutions/generative-AI/AssistGPT
eGain Knowledge Hub: https://www.egain.com/products/knowledge-hub/
No-charge production pilot: https://www.egain.com/try-chatgpt-for-cx/
About eGain
Infused with AI, our knowledge-powered software automates digital-first experiences for enterprises and government agencies. Pre-connected with leading CRM and contact center systems, the eGain platform delivers quick value and easy innovation with virtual assistance, customer self-service, and modern agent desktop tools. Visit www.eGain.com for more info.
eGain, the eGain logo, and all other eGain product names and slogans are trademarks or registered trademarks of eGain Corp. in the United States and/or other countries. All other company names and products mentioned in this release may be trademarks or registered trademarks of the respective companies.
eGain media contact
Michael Messner
Email: press@egain.com
Phone: 408 636 4514
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 20234.12.2023 22:30:00 CET | Press release
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights11/30/2023 96,431,770 Total gross of voting rights: 96,431,770 Total net* of voting rights: 96,186,256 * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.4.12.2023 22:16:59 CET | Press release
Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent to approximately $58.7 million) extending its runway into mid’ 2025 PARIS and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces today the closing of the previously announced subscription by Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”) for 901,256 additional ordinary shares of the Company, in the form of restricted American Depositary Shares (“ADSs”), for an aggregate amount of $4.8 million, equivalent to €4.6 million1 (the “Remaining Placement Amount”, and the subscription transaction being the “Remaining Placement”), following the approval by the French Ministry of Economy of JJ
Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH4.12.2023 22:05:00 CET | Press release
The DMC recommended to continue the clinical trial without modification of the protocol, based on the pre-planned review of safety dataThe safety assessment was based on the review of safety data from more than 500 patients, including patients that have been treated with lanifibranor for more than 72 weeksThe DMC review remains consistent, confirming the good safety profile of lanifibranor Daix (France), Long Island City (New York, United States), December 4, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the positive recommendation from the third meeting of the Data Monitoring Committee (DMC) to continue the NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH without modification to the trial protocol. The DMC
Standard Lithium to Participate in December Investor Conferences4.12.2023 22:04:35 CET | Press release
VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today announced its participation in the following virtual December investor conferences: Event:Deustche Bank 8th Annual Virtual Lithium Battery Supply Chain ConferenceDate:December 6, 2023Panel:US Based Lithium Supply, featuring Robert Mintak, CEO and Director of Standard Lithium, 7:45am – 8:15am PTEvent:Bank of America Securities Virtual 2023 Lithium and Battery Storage ConferenceDate:December 7, 2023Panel:Company Presentation, featuring Robert Mintak, CEO and Director of Standard Lithium, 7:45am – 8:30am PT Management will be hosting one-on-one meetings during the conferences. Interested investors should contact their Deutsche Bank or Bank of America representative or Standard Lithium Investor Relations at investors@standardlithium.com. About Standard Lithium Ltd. St
Resignation of Director4.12.2023 20:00:33 CET | Press release
December 4, 2023 Announcement no. 19 Resignation of Director COPENHAGEN, DENMARK and BOSTON, MA, USA, December 4, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) announced today that Jan Leth Christensen has informed the Company that he has decided to resign from his position as a board member for BioPorto. The search for a successor with relevant expertise, including familiarity with public company practices in the Nordics, will be initiated and a new candidate is expected to be proposed in connection with the Company’s Annual General Meeting in 2024. “Jan has served on the board since the Annual General Meeting held in 2021. I would like to thank Jan for his important contributions to the board and collaboration in general” said John McDonough, BioPorto’s Chaiman of the Board of Directors. For investor inquiries, please contact: HC Andersen Capital, EU Investor Relations, +45 4529 0000, investor@bioporto.com Ashley R. Robinson, US Investor Relations,